Check a POLE/POLD cancer drug for non–MSI-high tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old and have an advanced solid tumor confirmed by biopsy or cell testing
- Your tumor is POLE or POLD mutated (not just a “synonymous” change) and it is not MSI-H or dMMR
- Your cancer has measurable disease on scans, and your health status is good enough (ECOG 0–1)
- You must be willing to do tumor biopsies and blood tests before treatment and at check-in visits
- You must NOT have had treatment with PD-1/PD-L1/CTLA-4 or other immune checkpoint drugs in the past 4 weeks
- You are able to meet key blood/liver/organ lab levels (and for people who can become pregnant, you agree to pregnancy prevention)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.